Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BGM, unsubscribe in one click. Privacy
BGM holds $11.5M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BGM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Low Thia Yang | 5%+ holder (13D) | 38,165,290 | 106.76% | 2025-05-19 |
| AIFU Inc. | 5%+ holder (13D) | 16,529,330 | 46.24% | 2025-05-23 |
Share count 35,750,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BGM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →